Clinical studies of vaccines targeting breast cancer.
Many clinical studies have been undertaken to assess the therapeutic potential of vaccination and have included a large variety of cancer immunogens. Most of these studies involved patients with metastatic cancer, which is characterized by the most aggressive malignant cells, the longest-lasting disease, and the failure of all standard cytotoxic treatments. The presence of tumor over long periods and the toxicity of previous treatments tend to negatively affect immune responsiveness to tumor antigens presented by the vaccine. In this review, we analyze the ability of past and current vaccine therapies to induce clinical responses in breast cancer. To date, clinical responses have been observed by using vaccines targeting HER-2/neu protein, human telomerase reverse transcriptase, carcinoembryonic antigen, and carbohydrate antigen given after stem cell rescue. The review concludes with a discussion of possible future directions for vaccine development and applications.
Ko
Byung K
BK
Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Kawano
Kouichiro
K
Murray
James L
JL
Disis
Mary L
ML
Efferson
Clay L
CL
Kuerer
Henry M
HM
Peoples
George E
GE
Ioannides
Constantin G
CG
D000818:Animals; D000951:Antigens, Neoplasm / Q000737:chemistry; D001943:Breast Neoplasms / Q000188:drug therapy*; D019496:Cancer Vaccines; D002241:Carbohydrates / Q000737:chemistry; D002272:Carcinoembryonic Antigen / Q000096:biosynthesis; D004268:DNA-Binding Proteins; D006801:Humans; D008956:Models, Chemical; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D019098:Telomerase / Q000378:metabolism; D013997:Time Factors
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D002241:Carbohydrates; D002272:Carcinoembryonic Antigen; D004268:DNA-Binding Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D019098:Telomerase